|
Baseline characteristics
|
n (% or range)
|
|---|
|
Age
|
66 (45–79)
|
|
Baseline PSA (ng/mL)
|
79.7 (3.9–2356)
|
|
Baseline Hemoglobin (g/dL)
|
12.2 (9.3–14.5)
|
|
Baseline LDH (U/L)
|
241 (153–351)
|
|
Baseline Alkaline Phosphatase (U/L)
|
80 (56–643)
|
|
Baseline CTCs (in 10 mL blood)
|
12 (0–2107)
|
|
Prior treatment with:
|
|
Enzalutamide
|
16 (94%)
|
|
Abiraterone
|
11 (65%)
|
|
Both
|
10 (59%)
|
|
Prior immunotherapy
|
8 (47%)
|
|
Prior chemotherapy
|
11 (65%)
|
|
Gleason score
|
|
< 8
|
5 (29%)
|
|
8–10
|
12 (71%)
|
|
ECOG performance status
|
|
0
|
2 (12%)
|
|
1
|
14 (82%)
|
|
2
|
1 (6%)
|
|
Disease site:
|
|
Bone only
|
5 (29%)
|
|
Bone/soft tissue/viscera
|
12 (71%)
|
